SMMT (Summit Therapeutics) Total Stockholders Equity : $344.33 Mil (As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Summit Therapeutics Total Stockholders Equity?

Summit Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $344.33 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Summit Therapeutics's Book Value per Share for the quarter that ended in Mar. 2025 was $0.46. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Summit Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.02.

Summit Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Summit Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics Total Stockholders Equity Chart

Summit Therapeutics Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

79.45

83.28

126.65

77.69

388.75

Summit Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial															44.21	195.08	437.92	388.75	344.33

Summit Therapeutics (NAS:SMMT) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Summit Therapeutics's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(344.33	-	0)	/	741.609
	=	0.46

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Summit Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.543	+	2.907)	/	344.33
	=	0.02

Summit Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Summit Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics Inc (NAS:SMMT) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

601 Brickell Key Drive, Suite 1000, Miami, FL, USA, 33131

Website

https://www.smmttx.com

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Executives

Maky Zanganeh	director	51 ADAM WAY, ATHERTON CA 94027
Ankur Dhingra	officer: Chief Financial Officer	C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Manmeet Singh Soni	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Robert W Duggan	director, 10 percent owner, officer: See Remarks	611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Yu Xia	director	6 SHENNONG ROAD, TORCH DEVELOPMENT ZONE, ZHONGSHAN, GUANGDONG F4 528437
Robert F. Booth	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Alessandra Cesano	director	700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065
Urte Gayko	director	C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Kenneth A Clark	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Jeffrey R Maranian	officer: VP, Corporate Controller	C/O SUMMIT THERAPEUTICS INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Luhua Wang	director	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
David Jonathan Powell	officer: Chief Scientific Officer	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Camilla Graham	officer: Chief Clinical Affairs Officer	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ventzislav Stefanov	director, officer: See Remarks	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ujwala Mahatme	director	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142